Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

摘要: c Although the antiproteinuric response to antihypertensive treatment is main predictor of renoprotective efficacy in long-term renal disease, date, dose-finding studies antihypertensives have been based only on blood pressure. We aimed find optimal dose angiotensin II antagonist losartan. An open-label, dose-response study using subsequent 6-week periods was performed 10 nondiabetic patients with proteinuria 5.8 6 0.8 g/d and a mean arterial pressure 103 3.7 mm Hg without medication. All had normal moderately impaired function. After baseline period, five followed daily losartan 50 mg, 100 150 mg recovery At end each were measured. The consecutive doses similar (211.3 2.8% by 100-mg dose). reached at (230 8%). 50-mg (213 7%) less effective, 150-mg (228 8%) not more effective. A for reduction nephrotic range proteinuria. © 2001 National Kidney Foundation, Inc.